Drug Trial Radar · NCT03283826
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
134
Actual
Start
Oct 19, 2017
Primary completion
Nov 9, 2023
Study completion Jan 17, 2024
Sponsor
- Lead sponsor
- Atara BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis \[PPMS\] and secondary progressive multiple sclerosis \[SPMS\]).
Conditions
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
Interventions
ATA188Biological
ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
PlaceboDrug
Placebo matching to ATA188
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of adverse eventsTime frame: At 12 months after the first dose of study drug
- Part 1: Incidence of clinically significant changes in laboratory tests, electrocardiograms (ECGs), and vital signsTime frame: At 12 months after the first dose of study drug
- Part 1: Recommended Part 2 dose of ATA188 monotherapyTime frame: Day 1 to Day 35 of Cycle 1 for each participant in dose escalation part (approximately 1 year)
- Part 2: Percentage of participants with confirmed expanded disability status scale (EDSS) improvement at 12 monthsTime frame: At 12 months after the first dose of study drug
Locations
31 sites in 3 countries. Site status is shown where the registry gives one.
University of California, San Diego
La Jolla, California
Kaiser Permanente MS Clinic Los Angeles
Los Angeles, California
Stanford University
Palo Alto, California
University of California San Francisco
San Francisco, California
University of Colorado
Aurora, Colorado
Advanced Neurology
Fort Collins, Colorado
Neurology Associates, PA-Maitland
Maitland, Florida
University of South Florida, Morsani College of Medicine
Tampa, Florida
Fort Wayne Neurological Center
Fort Wayne, Indiana
University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center
Kansas City, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
Dragonfly Research
Wellesley, Massachusetts
Washington University in St. Louis
St Louis, Missouri
Dent Neurologic Institute
Amherst, New York
Columbia University Medical Center-The Neurological Institute of New York
New York, New York
University of Rochester Medical Center - URMC
Rochester, New York
PMG Research of Piedmont Healthcare
Mooresville, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
Premier Neurology P.C.
Greer, South Carolina
Advanced Neurosciences Institute ANI - Franklin
Franklin, Tennessee
Vanderbilt Comprehensive Multiple Sclerosis Center
Nashville, Tennessee
The University of Texas Health Science Center at Houston
Houston, Texas
MS Center of Greater Washington
Vienna, Virginia
Inland Northwest Research LLC
Spokane, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Liverpool Hospital
Liverpool, New South Wales, Australia
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia
Griffith University, School of Medicine
Southport, Queensland, Australia
Fraser Health Multiple Sclerosis Clinic
Burnaby, British Columbia, Canada
Unity Health Toronto/St. Michael's Hospital
Toronto, Ontario, Canada
Recherche Sepmus Inc.
Greenfield Park, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.